Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.
- Mechanism
- Curator reviewed
The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.
- Primary indication
- For the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers.Curator reviewed
- Formula / weight
- C19H28N2O4 · 348.4366 g/mol (avg)
- Also known as
- Pifatidine
Resolves to
SMTZFNFIKUPEJC-UHFFFAOYSA-NSMILESCC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Roxatidine acetate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account